STOCK TITAN

Immutep Limited American Depositary Shares - IMMP STOCK NEWS

Welcome to our dedicated page for Immutep American Depositary Shares news (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep American Depositary Shares stock.

Immutep Limited (NASDAQ: IMMP) is a globally active biotechnology company focusing on the development of innovative immunotherapy products for cancer and autoimmune diseases. Listed on both the Australian Stock Exchange and the Nasdaq Global Market in the U.S., Immutep is at the forefront of personalized bio-therapeutic treatment options.

At the core of Immutep's research and development is the LAG-3 immune control mechanism, crucial for the regulation of the T cell immune response. The company's flagship product, IMP321, a T cell immunostimulatory factor (APC activator), has completed Phase II clinical trials for cancer chemo-immunotherapy. This product is designed to enhance the body's immune response to cancer, providing a novel treatment option for patients.

In addition to IMP321, Immutep is advancing several other LAG-3 related products. These include IMP701, a blocking anti-LAG-3 antibody for cancer currently in Phase I clinical trials, and CVac, a personalized immunocellular therapeutic being investigated for the treatment of epithelial cancer. The development of these products is supported through partnerships with large pharmaceutical companies, aiming to accelerate the availability of these innovative treatments.

Immutep's operations are headquartered in Australia, with the majority of its revenue derived from product sales. The company remains committed to maximizing shareholder value through its technological expertise and robust pipeline of products.

For investors, Immutep represents a significant opportunity in the biotechnology sector, with its cutting-edge research and promising clinical advancements poised to make a substantial impact on cancer and autoimmune disease treatment.

Rhea-AI Summary
Immutep Limited announces that data from its TACTI-002 Phase II trial evaluating the combination of eftilagimod alpha and KEYTRUDA® has been accepted for presentation at the 2023 ESMO Congress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces the enrollment of the first patient in EFTISARC-NEO, a Phase II trial of eftilagimod alpha (efti) in combination with radiotherapy and KEYTRUDA® for soft tissue sarcoma. The trial aims to evaluate the potential synergistic effects of this chemo-free therapy, addressing the high unmet medical need for soft tissue sarcoma treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.39%
Tags
none

FAQ

What is the current stock price of Immutep American Depositary Shares (IMMP)?

The current stock price of Immutep American Depositary Shares (IMMP) is $2.03 as of December 20, 2024.

What is the market cap of Immutep American Depositary Shares (IMMP)?

The market cap of Immutep American Depositary Shares (IMMP) is approximately 311.3M.

What is Immutep Limited?

Immutep Limited is a biotechnology company developing innovative immunotherapy products for cancer and autoimmune diseases.

What products does Immutep specialize in?

Immutep specializes in products based on the LAG-3 immune control mechanism, including IMP321 for cancer chemo-immunotherapy, and other LAG-3 related products like IMP701 and CVac.

What is the LAG-3 immune control mechanism?

The LAG-3 immune control mechanism is crucial for regulating the T cell immune response and is used by Immutep in developing therapies for cancer and autoimmune diseases.

What is IMP321?

IMP321 is a T cell immunostimulatory factor (APC activator) developed by Immutep for cancer chemo-immunotherapy. It has completed Phase II clinical trials.

What are the other key products in Immutep's pipeline?

Other key products include IMP701, a blocking anti-LAG-3 antibody for cancer, and CVac, a personalized immunocellular therapeutic for epithelial cancer.

With which markets is Immutep affiliated?

Immutep is listed on the Australian Stock Exchange and the Nasdaq Global Market in the U.S.

Where is Immutep headquartered?

Immutep is headquartered in Australia.

What are Immutep's key partnerships?

Immutep collaborates with large pharmaceutical companies to develop and bring its products to market.

How does Immutep generate revenue?

Immutep generates the majority of its revenue from the sale of its biotechnology products.

Why should investors consider Immutep?

Investors should consider Immutep for its cutting-edge research, promising clinical advancements in immunotherapy, and strategic partnerships.

Immutep Limited American Depositary Shares

Nasdaq:IMMP

IMMP Rankings

IMMP Stock Data

311.28M
145.44M
0.01%
6.26%
3.53%
Biotechnology
Healthcare
Link
United States of America
Sydney